Great Lakes Advisors LLC Cuts Stock Position in DexCom, Inc. $DXCM

Great Lakes Advisors LLC decreased its position in shares of DexCom, Inc. (NASDAQ:DXCM) by 70.6% in the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 4,740 shares of the medical device company’s stock after selling 11,407 shares during the period. Great Lakes Advisors LLC’s holdings in DexCom were worth $319,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors and hedge funds have also bought and sold shares of the company. Annis Gardner Whiting Capital Advisors LLC increased its position in shares of DexCom by 6,670.1% during the third quarter. Annis Gardner Whiting Capital Advisors LLC now owns 7,244 shares of the medical device company’s stock worth $487,000 after purchasing an additional 7,137 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. grew its stake in DexCom by 11.2% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 212,045 shares of the medical device company’s stock worth $14,269,000 after buying an additional 21,352 shares during the last quarter. Hussman Strategic Advisors Inc. acquired a new position in DexCom during the 3rd quarter valued at about $2,826,000. Intact Investment Management Inc. raised its stake in DexCom by 102.9% in the third quarter. Intact Investment Management Inc. now owns 33,890 shares of the medical device company’s stock valued at $2,280,000 after buying an additional 17,190 shares during the last quarter. Finally, MBM Wealth Consultants LLC boosted its holdings in DexCom by 4.1% in the third quarter. MBM Wealth Consultants LLC now owns 9,228 shares of the medical device company’s stock worth $621,000 after acquiring an additional 361 shares in the last quarter. 97.75% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

DXCM has been the topic of several recent analyst reports. Weiss Ratings restated a “sell (d+)” rating on shares of DexCom in a report on Monday, December 29th. Evercore ISI assumed coverage on shares of DexCom in a report on Tuesday, November 25th. They issued an “in-line” rating and a $68.00 price target for the company. Argus dropped their price objective on shares of DexCom from $100.00 to $90.00 and set a “buy” rating on the stock in a report on Friday, November 7th. JPMorgan Chase & Co. reduced their target price on DexCom from $90.00 to $75.00 and set a “neutral” rating for the company in a research note on Friday, October 31st. Finally, Robert W. Baird set a $82.00 price target on DexCom in a research note on Friday, October 31st. Two analysts have rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating, four have issued a Hold rating and two have issued a Sell rating to the company. Based on data from MarketBeat.com, DexCom currently has an average rating of “Moderate Buy” and an average target price of $85.00.

DexCom Stock Performance

Shares of DXCM stock opened at $72.53 on Tuesday. DexCom, Inc. has a 52-week low of $54.11 and a 52-week high of $93.25. The company has a quick ratio of 1.38, a current ratio of 1.56 and a debt-to-equity ratio of 0.45. The stock has a market cap of $28.29 billion, a PE ratio of 40.29, a price-to-earnings-growth ratio of 1.31 and a beta of 1.49. The business has a 50-day simple moving average of $68.02 and a 200-day simple moving average of $70.59.

Insiders Place Their Bets

In other news, Director Bridgette P. Heller sold 1,012 shares of the firm’s stock in a transaction that occurred on Wednesday, November 12th. The shares were sold at an average price of $58.07, for a total transaction of $58,766.84. Following the sale, the director owned 27,031 shares of the company’s stock, valued at $1,569,690.17. This trade represents a 3.61% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, Director Richard Alexander Collins sold 2,906 shares of the business’s stock in a transaction on Friday, November 14th. The shares were sold at an average price of $59.05, for a total transaction of $171,599.30. Following the completion of the transaction, the director owned 35,088 shares of the company’s stock, valued at approximately $2,071,946.40. This represents a 7.65% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last 90 days, insiders have sold 7,866 shares of company stock worth $448,177. Corporate insiders own 0.32% of the company’s stock.

DexCom Profile

DexCom, Inc is a medical device company that develops, manufactures and distributes continuous glucose monitoring (CGM) systems for people with diabetes. Its products are designed to provide near real-time glucose readings, trend information and alerts to help patients and clinicians manage insulin dosing and reduce hypoglycemia and hyperglycemia. The company’s offerings combine wearable glucose sensors, wireless transmitters and software applications that deliver data to smartphones, dedicated receivers and cloud-based platforms for remote monitoring.

Founded in 1999 and headquartered in San Diego, California, DexCom has focused its business on advancing CGM technology and expanding clinical use beyond traditional insulin-dependent populations.